Research Papers:

A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility

Yajing Zhai, Zhijun Dai, Hairong He, Fan Gao, Lihong Yang, Yalin Dong and Jun Lu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:73935-73944. https://doi.org/10.18632/oncotarget.12558

Metrics: PDF 1228 views  |   HTML 1768 views  |   ?  


Yajing Zhai1,*, Zhijun Dai2,*, Hairong He3, Fan Gao3, Lihong Yang3, Yalin Dong1, Jun Lu3

1Department of Pharmacy, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, China

2Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, China

3Clinical Research Center, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, 710061, China

*These authors have contributed equally to this work

Correspondence to:

Jun Lu, email: [email protected]

Keywords: MDM4, polymorphism, cancer susceptibility, meta-analysis

Received: August 16, 2016     Accepted: October 04, 2016     Published: October 11, 2016


Molecular epidemiological research suggests that mouse double minute 4 (MDM4) polymorphisms may be associated with cancer susceptibility, but results remain controversial. To derive a more precise evaluation, we performed a PRISMA compliant meta-analysis focused on five single nucleotide polymorphisms (rs11801299, rs1380576, rs10900598, rs1563828, and rs4245739) of MDM4. Overall, 23 studies involving 22,218 cases and 55,033 controls were analyzed. The results showed that rs4245739 was significantly associated with a decreased cancer risk in the allelic (C vs. A: odds ratio [OR] = 0.848, 95% confidence interval [CI] = 0.765–0.941, P = 0.002), heterozygous (AC vs. AA: OR = 0.831, 95% CI = 0.735–0.939, P = 0.003), and dominant (AC+CC vs. A: OR = 0.823, 95% CI = 0.727–0.932, P = 0.002) models. The association was more prominent in Asians. No significant association was found using any genetic model for the rs11801299, rs1380576, rs10900598, and rs1563828 SNPs. These results indicate that the rs4245739 polymorphism may contribute to a decreased cancer susceptibility and support the hypothesis that genetic variants in the MDM4 genes act as important modifiers of cancer risk.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12558